Oligonucleotide therapeutics: How to measure plasma concentration, tissue distribution and immunogenicity?

Oligonucleotide therapeutics: How to measure plasma concentration, tissue distribution and immunogenicity?

Whitepapers

Oligonucleotides are becoming increasingly important as therapeutic agents. Since the commercial launch of the first oligonucleotide therapeutic (ONT) in 1998 (Vitravene®), ten ONT products have received market approval, the majority of which were approved in the last four years. ONTs share properties with chemical (e.g. they are synthesized via chemical processes) and biological pharmaceuticals (e.g. in terms of selective tissue distribution), and therefore present unique development challenges. The preclinical safety evaluation for ONTs has generally followed the regulatory guidelines for small molecule pharmaceuticals. However, ONTs may elicit an immune response, just like biotechnology-derived products do, and therefore require the assessment of immunogenicity. Quantification of ONTs in biological matrices is also conducted using the techniques applied for biological drugs.

This document presents a short overview of the industry-standard techniques used for the measurement of plasma concentration, tissue distribution and immunogenicity of ONT products.

Interested in reading the full resource?

Please fill out the form to unlock the rest of the content.

Latest Resources

Our team members share deep, scientific understanding and insights into their respective fields of expertise.

Want to hear more from Ardena?

Sign up to receive drug development insights, the latest on industry trends & Ardena news.

Stay up to date with our latest news and announcements.
Get deep, scientific understanding and insights into our key fields of expertise.
See the events we're attending and register for webinars we're hosting.